Nayak, Digant http://orcid.org/0000-0003-3680-0846
Lv, Dongwen http://orcid.org/0000-0003-4677-8996
Yuan, Yaxia
Zhang, Peiyi
Hu, Wanyi
Nayak, Anindita
Ruben, Eliza A.
Lv, Zongyang
Sung, Patrick http://orcid.org/0000-0003-1396-9040
Hromas, Robert
Zheng, Guangrong http://orcid.org/0000-0002-8106-6663
Zhou, Daohong
Olsen, Shaun K. http://orcid.org/0000-0002-1265-7101
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM115568, R01 GM128731)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 24 February 2023
Accepted: 14 March 2024
First Online: 29 March 2024
Competing interests
: G.Z., R.H., and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops BCL-xL/2 PROTACs to treat cancer. Other authors declare no competing interests.